Gabelli Funds’s AstraZeneca AZN Stock Holding History

Gabelli Funds’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.77M	Sell	19,100 -12,400	-39%	-$2.39M	0.03%	573
2025 Q4	$5.79M	Sell	31,500 -4,650	-13%	-$816K	0.04%	451
2025 Q3	$5.55M	Hold	36,150	–	–	0.04%	466
2025 Q2	$5.05M	Hold	36,150	–	–	0.04%	489
2025 Q1	$5.31M	Hold	36,150	–	–	0.04%	449
2024 Q4	$4.74M	Sell	36,150 -440	-1%	-$61.6K	0.04%	457
2024 Q3	$5.7M	Sell	36,590 -10	-0%	-$1.61K	0.04%	428
2024 Q2	$5.71M	Sell	36,600 -7,999	-18%	-$1.2M	0.04%	413
2024 Q1	$6.04M	Sell	44,599 -3,250	-7%	-$430K	0.04%	410
2023 Q4	$6.45M	Buy	47,849 +450	+0.9%	+$58.5K	0.05%	387
2023 Q3	$6.42M	Buy	47,399 +250	+0.5%	+$34.1K	0.05%	378
2023 Q2	$6.75M	Sell	47,149 -2,500	-5%	-$368K	0.05%	389
2023 Q1	$6.89M	Sell	49,649 -1,900	-4%	-$256K	0.05%	390
2022 Q4	$6.99M	Sell	51,549 -2,093	-4%	-$262K	0.05%	381
2022 Q3	$6.63M	Sell	53,642 -2,500	-4%	-$317K	0.05%	386
2022 Q2	$7.42M	Sell	56,142 -500	-0.9%	-$65.6K	0.06%	380
2022 Q1	$7.51M	Sell	56,642 -1,750	-3%	-$210K	0.05%	407
2021 Q4	$6.8M	Sell	58,392 -7,566	-11%	-$890K	0.04%	437
2021 Q3	$7.92M	Buy	65,958 +61,708	+1,452%	+$7.18M	0.05%	397
2021 Q2	$509K	Sell	4,250 -5,845	-58%	-$641K	﹤0.01%	1047
2021 Q1	$1M	Sell	10,095 -5,155	-34%	-$518K	0.01%	899
2020 Q4	$1.52M	Sell	15,250 -5,250	-26%	-$556K	0.01%	779
2020 Q3	$2.25M	Sell	20,500 -19,000	-48%	-$2.11M	0.02%	647
2020 Q2	$4.18M	Sell	39,500 -6,500	-14%	-$671K	0.03%	478
2020 Q1	$4.11M	Hold	46,000	–	–	0.04%	456
2019 Q4	$4.59M	Sell	46,000 -3,000	-6%	-$282K	0.03%	519
2019 Q3	$4.37M	Sell	49,000 -16,000	-25%	-$1.39M	0.03%	549
2019 Q2	$5.37M	Sell	65,000 -2,000	-3%	-$157K	0.03%	499
2019 Q1	$5.42M	Sell	67,000 -1,000	-1%	-$78.8K	0.03%	511
2018 Q4	$5.17M	Sell	68,000 -6,500	-9%	-$508K	0.04%	497
2018 Q3	$5.9M	Sell	74,500 -17,500	-19%	-$1.32M	0.03%	530
2018 Q2	$6.46M	Sell	92,000 -5,000	-5%	-$360K	0.04%	495
2018 Q1	$6.78M	Sell	97,000 -2,500	-3%	-$173K	0.04%	466
2017 Q4	$6.91M	Buy	99,500 +1,500	+2%	+$101K	0.04%	485
2017 Q3	$6.64M	Buy	98,000 +7,200	+8%	+$455K	0.04%	503
2017 Q2	$6.19M	Sell	90,800 -4,200	-4%	-$274K	0.04%	505
2017 Q1	$5.92M	Sell	95,000 -3,500	-4%	-$204K	0.03%	516
2016 Q4	$5.38M	Buy	98,500 +3,500	+4%	+$199K	0.03%	529
2016 Q3	$6.24M	Sell	95,000 -2,000	-2%	-$131K	0.04%	485
2016 Q2	$5.86M	Sell	97,000 -7,450	-7%	-$433K	0.03%	511
2016 Q1	$5.88M	Sell	104,450 -3,000	-3%	-$180K	0.04%	506
2015 Q4	$7.3M	Sell	107,450 -7,000	-6%	-$459K	0.04%	456
2015 Q3	$7.28M	Sell	114,450 -2,000	-2%	-$132K	0.04%	465
2015 Q2	$7.42M	Sell	116,450 -1,100	-0.9%	-$75.3K	0.04%	486
2015 Q1	$8.04M	Sell	117,550 -34,000	-22%	-$2.36M	0.04%	482
2014 Q4	$10.7M	Sell	151,550 -28,000	-16%	-$2M	0.05%	426
2014 Q3	$12.8M	Buy	179,550 +6,500	+4%	+$476K	0.07%	370
2014 Q2	$12.9M	Buy	+173,050	New	+$12.5M	0.06%	381

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Gabelli Funds's AZN Position: Q1 2026 in Review

Gabelli Funds reduced its AstraZeneca (AZN) stake by 39% in Q1 2026, selling an estimated $2.39M and leaving 19,100 shares worth $3.77M. The position accounts for 0.03% of the portfolio, ranked #573.

Gabelli Funds first reported a position in AZN in Q2 2014 and has held it in 48 quarters since. The position peaked at $12.9M in Q2 2014. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Gabelli Funds held 19,100 shares of AstraZeneca worth $3.77M as of Q1 2026.
Gabelli Funds sold 12,400 AstraZeneca shares in Q1 2026, an estimated $2.39M.
AstraZeneca made up 0.03% of Gabelli Funds's portfolio in Q1 2026, its #573 holding.
Gabelli Funds first reported a position in AstraZeneca in Q2 2014 and has held it in 48 quarters since.
Gabelli Funds's AstraZeneca position peaked at $12.9M in Q2 2014.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Gabelli Funds's 13F filing for Q1 2026, filed 14 May 2026.